Drugs / Quadrivalent Influenza High-Dose Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06361875 Comparator | Apr 2024 → Jun 2025 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT05650554 Comparator | Dec 2022 → Apr 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT05553301 Comparator | Oct 2022 → Jan 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Influenza High-Dose Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05553301 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza High-Dose Vaccine” NCT05553301 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular Injection” NCT05553301 ↗ |